Jade Biosciences, Inc. (JBIO) - 10-K Summary
Business Context and Reporting Period
Company: Jade Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Jade is a clinical-stage biopharmaceutical company developing novel biologic therapies for autoimmune diseases. The company operates as a single segment focused on three product candidates: JADE101 (anti-APRIL for IgA nephropathy), JADE201 (anti-BAFF-R for multiple autoimmune disorders), and JADE301 (undisclosed target).
Corporate Status: The company became a public entity via a reverse recapitalization with Aerovate Therapeutics, Inc. on April 28, 2025, and is incorporated in Nevada. It is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric | Year Ended Dec 31, 2025 | Period Ended Dec 31, 2024 (Inception) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(127.4) million | $(47.0) million |
| Accumulated Deficit | $(174.4) million | $(47.0) million |
| Operating Expenses | $113.5 million | $35.5 million |
| Research & Development (R&D) | $93.1 million | $31.2 million |
| General & Administrative (G&A) | $20.4 million | $4.3 million |
| Cash & Cash Equivalents | $88.4 million | $69.4 million |
| Investments | $247.7 million | $0 |
| Total Liquidity (Cash + Investments) | $336.2 million | $69.4 million |
| Net Cash Used in Operating Activities | $(94.7) million | $(22.6) million |
| Net Cash Provided by Financing Activities | $360.8 million | $92.0 million |
Note: The company has no debt outstanding as of December 31, 2025, following the conversion of convertible notes into equity during the reverse recapitalization.
Material Changes vs. Prior Period
- Significant Capital Raises: The company raised substantial capital in 2025, including $205.0 million from the Pre-Closing Financing, $135.0 million from an October 2025 PIPE, and $45.0 million from a December 2025 PIPE. This contrasts with $95.0 million raised via convertible notes in 2024.
- Expense Growth: Total operating expenses increased by $78.0 million (219%) year-over-year. R&D expenses rose by $61.9 million, driven by clinical trial initiation for JADE101, toxicology studies, and milestone payments to Paragon Therapeutics. G&A expenses increased by $16.1 million due to public company compliance costs and personnel expansion.
- Non-Cash Items: A significant non-cash charge of $21.6 million was recorded in 2025 related to the change in fair value of convertible notes payable prior to their conversion. Stock-based compensation expense increased to $20.0 million in 2025 from $1.3 million in 2024.
- Investment Activity: The company deployed $247.0 million in investing activities in 2025, primarily purchasing marketable securities, compared to no investing activity in 2024.
Guidance, Outlook, and Risks
Development Outlook:
- JADE101: Phase 1 trial in healthy volunteers initiated in August 2025 (New Zealand). Interim data expected Q2 2026. Phase 2 in IgAN patients planned for mid-2026, with interim data expected in 2027.
- JADE201: Phase 1 trial in rheumatoid arthritis patients planned for Q2 2026, with interim data expected in 2027.
- JADE301: Phase 1 trial expected to initiate in the first half of 2027.
Liquidity: Management expects existing cash and investments ($336.2 million) to fund operations for at least 12 months from the filing date. No committed external funding sources exist beyond current cash.
Key Risks and Contingencies:
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to advance clinical trials and commercialization.
- Third-Party Reliance: The company relies heavily on Paragon Therapeutics for discovery and licensing, and on third-party CMOs (including WuXi Biologics) for manufacturing. Disruptions in these relationships or geopolitical issues (e.g., U.S. BIOSECURE Act) could impact operations.
- Regulatory Uncertainty: As a clinical-stage company with no approved products, success depends on obtaining regulatory approvals, which are lengthy, expensive, and uncertain.
- Competition: The IgAN market is competitive with recently approved therapies (e.g., Voyxact, Vanrafia) and multiple candidates in late-stage development.
Investor Verification Checklist
- Cash Runway: Verify the $336.2 million liquidity position and confirm the 12-month burn rate projection given the accelerated clinical timeline.
- Paragon Agreements: Review the specific milestone payment obligations (up to $22.0 million per program) and royalty rates under the Paragon License Agreements.
- Manufacturing Risks: Assess the impact of the U.S. BIOSECURE Act on the company's reliance on WuXi Biologics for manufacturing.
- Clinical Milestones: Monitor the Q2 2026 interim data readout for JADE101 in healthy volunteers as a critical validation point for the IgAN program.
- Dilution: Track the impact of outstanding pre-funded warrants and stock options (approx. 10.9 million potentially dilutive securities) on future equity value.